Details of the Drug
General Information of Drug (ID: DMD2QVO)
Drug Name |
2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
7-Benzyloxytryptamine; 31677-75-5; 2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine; CHEMBL460302; 2-[7-(benzyloxy)-1h-indol-3-yl]ethanamine; JOYGWYISRWPUIM-UHFFFAOYSA-N; 3-(2-AMINOETHYL)-7-BENZYLOXYINDOLE; 1H-Indole-3-ethanamine,7-(phenylmethoxy)-; B-2160; NSC92541; 7-Benzyloxytriptamine; AC1Q57HL; SCHEMBL5167328; AC1L63X1; CTK4G7564; ZINC39096; 7-Benzyloxytryptamine, free base; DTXSID60293835; 6038AH; NSC-92541; BDBM50247069; AKOS024282335; 7-(Benzyloxy)-1H-indole-3-ethanamine; MCULE-8072963757; ACM31677755; ST055630
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 266.34 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||